Irbesartan-loaded cRGD-modified PLGA nanoparticles attenuate intervertebral disc degeneration through an FGFR1-related mechanism

BACKGROUND: Intervertebral disc degeneration (IDD) lacks effective disease-modifying therapy. This study evaluated the protective effects of irbesartan (Ir), explored fibroblast growth factor receptor 1 (FGFR1) as a candidate molecular mediator, and assessed whether cRGD modification could enhance nanoparticle uptake and local treatment effects. METHODS: Rat IDD models and IL-1β-induced degenerative nucleus pulposus cells were used to assess free Ir and Ir-loaded cRGD-modified PLGA nanoparticles (cRGD-NPs@Ir). Bioinformatics screening, cellular thermal shift assay (CETSA), and molecular docking were used to nominate FGFR1 as a candidate Ir-associated protein, and FGFR1 knockdown was used to test whether FGFR1 status modified the treatment response. Imaging, histology, immunohistochemistry, Western blotting, RT-qPCR, nanoparticle characterization, Coumarin-6 uptake assays, and tandem LC3 reporter analysis were used to evaluate treatment-associated changes. RESULTS: Ir attenuated structural and molecular features of IDD, reduced MAPK/NF-κB signaling, altered autophagy-associated markers, and preserved extracellular matrix homeostasis. FGFR1 expression was lower in degenerative disc tissue, and FGFR1 knockdown attenuated several protective changes associated with Ir or cRGD-NPs@Ir. cRGD-NPs@Ir produced greater carrier-associated Coumarin-6 uptake than NPs@Ir and larger treatment-associated changes than free Ir for several directly compared endpoints. These findings support an FGFR1-related component of the response but do not establish direct Ir-FGFR1 binding, receptor-specific cRGD targeting, or exclusive FGFR1 dependence. CONCLUSIONS: FGFR1 may contribute as a candidate molecular mediator to Ir-associated changes in autophagy and inflammatory signaling in IDD. cRGD-NPs@Ir provides an uptake-enhancing local nanodelivery strategy, although receptor specificity and direct Ir-FGFR1 binding require further validation.

Authors

Institutions

Publication Details

Journal
Biomarker Research
Published
2026-11-18
DOI
https://doi.org/10.1186/s40364-026-01041-8
Primary Topic
Spine and Intervertebral Disc Pathology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Irbesartan-loaded cRGD-modified PLGA nanoparticles attenuate intervertebral disc degeneration through an FGFR1-related mechanism

Shanxi Wang, Ren-Ji Wang, Ying-Guang Wang, Liang Yan et al.
Biomarker Research
Spine and Intervertebral Disc Pathology
article

Irbesartan-loaded cRGD-modified PLGA nanoparticles attenuate intervertebral disc degeneration through an FGFR1-related mechanism

Shanxi Wang, Ren-Ji Wang, Ying-Guang Wang, Liang Yan, Jian-Bin Guan, Rong-Jin Luo, Ling-Jiang Li, Kai-Yuan Lin, Si-Bo Wang, Xiao-Jun Yu
article en

Abstract

BACKGROUND: Intervertebral disc degeneration (IDD) lacks effective disease-modifying therapy. This study evaluated the protective effects of irbesartan (Ir), explored fibroblast growth factor receptor 1 (FGFR1) as a candidate molecular mediator, and assessed whether cRGD modification could enhance nanoparticle uptake and local treatment effects. METHODS: Rat IDD models and IL-1β-induced degenerative nucleus pulposus cells were used to assess free Ir and Ir-loaded cRGD-modified PLGA nanoparticles (cRGD-NPs@Ir). Bioinformatics screening, cellular thermal shift assay (CETSA), and molecular docking were used to nominate FGFR1 as a candidate Ir-associated protein, and FGFR1 knockdown was used to test whether FGFR1 status modified the treatment response. Imaging, histology, immunohistochemistry, Western blotting, RT-qPCR, nanoparticle characterization, Coumarin-6 uptake assays, and tandem LC3 reporter analysis were used to evaluate treatment-associated changes. RESULTS: Ir attenuated structural and molecular features of IDD, reduced MAPK/NF-κB signaling, altered autophagy-associated markers, and preserved extracellular matrix homeostasis. FGFR1 expression was lower in degenerative disc tissue, and FGFR1 knockdown attenuated several protective changes associated with Ir or cRGD-NPs@Ir. cRGD-NPs@Ir produced greater carrier-associated Coumarin-6 uptake than NPs@Ir and larger treatment-associated changes than free Ir for several directly compared endpoints. These findings support an FGFR1-related component of the response but do not establish direct Ir-FGFR1 binding, receptor-specific cRGD targeting, or exclusive FGFR1 dependence. CONCLUSIONS: FGFR1 may contribute as a candidate molecular mediator to Ir-associated changes in autophagy and inflammatory signaling in IDD. cRGD-NPs@Ir provides an uptake-enhancing local nanodelivery strategy, although receptor specificity and direct Ir-FGFR1 binding require further validation.

Biomarker ResearchVol. 14(1)
Xi'an Honghui Hospital (CN), Xi'an Jiaotong University (CN)
Good health and well-being
Spine and Intervertebral Disc Pathology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon